Study #2016-0783
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Poziotinib
Description
This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth..
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Study phase:
Phase II
Physician name:
Yasir Elamin
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.